Next Article in Journal
Quantitative Analysis of Residual COVID-19 Lung CT Features: Consistency among Two Commercial Software
Previous Article in Journal
New Approach to the Old Challenge of Free Flap Monitoring—Hyperspectral Imaging Outperforms Clinical Assessment by Earlier Detection of Perfusion Failure
Previous Article in Special Issue
Tumour Genome Characterization of a Rare Case of Pulmonary Enteric Adenocarcinoma and Prior Colon Adenocarcinoma
Review

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

1
Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia
2
Hopp Children’s Cancer Center (KiTZ), 69120 Heidelberg, Germany
3
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
4
German Cancer Consortium (DKTK), 69120 Heidelberg, Germany
5
Clinical Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
6
Diagnostic and Research Institute of Pathology, Medical University of Graz, 8010 Graz, Austria
7
Faculties for Dental Medicine and Health, University of Osijek, 31000 Osijek, Croatia
*
Author to whom correspondence should be addressed.
These authors equally contributed.
These authors share senior authorship.
Academic Editor: Alessandra Pulliero
J. Pers. Med. 2021, 11(11), 1102; https://doi.org/10.3390/jpm11111102
Received: 24 August 2021 / Revised: 21 October 2021 / Accepted: 25 October 2021 / Published: 27 October 2021
(This article belongs to the Special Issue Lung Cancer and Personalized Medicine)
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the “one-fits-all” paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer. View Full-Text
Keywords: lung cancer; adenocarcinoma; squamous cell lung cancer; biomarker; diagnosis; prognosis; targeted therapy; immunotherapy lung cancer; adenocarcinoma; squamous cell lung cancer; biomarker; diagnosis; prognosis; targeted therapy; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Šutić, M.; Vukić, A.; Baranašić, J.; Försti, A.; Džubur, F.; Samaržija, M.; Jakopović, M.; Brčić, L.; Knežević, J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. J. Pers. Med. 2021, 11, 1102. https://doi.org/10.3390/jpm11111102

AMA Style

Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, Jakopović M, Brčić L, Knežević J. Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. Journal of Personalized Medicine. 2021; 11(11):1102. https://doi.org/10.3390/jpm11111102

Chicago/Turabian Style

Šutić, Maja, Ana Vukić, Jurica Baranašić, Asta Försti, Feđa Džubur, Miroslav Samaržija, Marko Jakopović, Luka Brčić, and Jelena Knežević. 2021. "Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management" Journal of Personalized Medicine 11, no. 11: 1102. https://doi.org/10.3390/jpm11111102

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop